학술논문
ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy.
Document Type
Article
Author
Bousquet, Jean; Pfaar, Oliver; Agache, Ioana; Bedbrook, Anna; Akdis, Cezmi A; Canonica, G. Walter; Chivato, Tomas; Al‐Ahmad, Mona; Abdul Latiff, Amir H; Ansotegui, Ignacio J; Bachert, Claus; Baharuddin, Abdullah; Bergmann, Karl‐Christian; Bindslev‐Jensen, Carsten; Bjermer, Leif; Bonini, Matteo; Bosnic‐Anticevich, Sinthia; Bosse, Isabelle; Brough, Helen A.; Brussino, Luisa
Source
Subject
*RESPIRATORY allergy
*RHINITIS
*ALLERGENS
*PATIENT compliance
*IMMUNOTHERAPY
*MEDICAL personnel
*PHYSICIANS
*
*
*
*
*
*
Language
ISSN
2045-7022
Abstract
AIT is a proven therapeutic option for the treatment of allergic rhinitis, conjunctivitis, and/or asthma using sublingual (SLIT) or subcutaneous (SCIT) routes. Keywords: allergic rhinitis; asthma; immunotherapy; precision medicine EN allergic rhinitis asthma immunotherapy precision medicine 1 11 11 06/25/21 20210601 NES 210601 INTRODUCTION Allergen immunotherapy (AIT), the gradually increasing repeated administration of high doses of allergens to allergic patients, offers the potential for immune tolerance against reactions to the natural exposures to specific allergens. Allergic rhinitis, asthma, immunotherapy, precision medicine For patients with concomitant allergic rhinitis and sensitised to house dust mite - with persisting asthma symptoms despite low-moderate dose of inhaled corticosteroids - SLIT can be considered, provided FEV1 is >70% predicted. [Extracted from the article]